DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer

Vincenzo Di Noia, Michele Basso, Valentina Marsico, Eleonora Cerchiaro, Sabrina Rossi, Ettore D'Argento, Antonia Strippoli, Giovanni Schinzari, Roberto Iezzi, Alessandra Cassano, Carlo Antonio Barone

Research output: Contribution to journalArticle

Abstract

Aim: This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases. Patients & methods: Forty patients with liver-limited or liver-dominant disease, who have failed at least two previous lines of chemotherapy, underwent either four DEBIRI at 2-week interval or two DEBIRI every 4 weeks for bilobar or single-lobe metastases, respectively. Capecitabine was given at 1000 mg/m2 twice-daily on days 1-14 every 3 weeks. Results: Seven partial responses and 12 stable diseases were observed, achieving a disease control rate of 47.5%. Median progression-free survival and overall survival resulted 4 and 8 months, respectively. Grade 3 adverse events occurred in 6/40 points (15%) of patients. Conclusion: DEBIRI plus capecitabine is a valid treatment option for heavily pretreated patients with colorectal cancer liver metastases.

Original languageEnglish
Pages (from-to)2349-2360
Number of pages12
JournalFuture Oncology
Volume15
Issue number20
DOIs
Publication statusPublished - Jul 2019

    Fingerprint

Cite this

Di Noia, V., Basso, M., Marsico, V., Cerchiaro, E., Rossi, S., D'Argento, E., Strippoli, A., Schinzari, G., Iezzi, R., Cassano, A., & Barone, C. A. (2019). DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. Future Oncology, 15(20), 2349-2360. https://doi.org/10.2217/fon-2017-0025